<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185090</url>
  </required_header>
  <id_info>
    <org_study_id>ID-VARE-101</org_study_id>
    <nct_id>NCT04185090</nct_id>
  </id_info>
  <brief_title>To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults</brief_title>
  <official_title>An Open-label, Single or Multiple-dose, Fixed-sequence, 3-treatment, 3-Period Phase 1 Study to Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designated to evaluate the pharmacokinetic interactions of valsartan,
      amlodipine besylate, rosuvastatin, and ezetimibe in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Single or Multiple-dose, Fixed-sequence, 3-treatment, 3-Period phase 1 study
      to Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety between ID1801 and
      ID1803 in Healthy Male Subjects
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ(Amlodipine, valsartan, rosuvastatin, free ezetimibe)</measure>
    <time_frame>0~72hours</time_frame>
    <description>Amlodipine, valsartan, rosuvastatin, free ezetimibe: AUCτ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss(Amlodipine, valsartan, rosuvastatin, free ezetimibe)</measure>
    <time_frame>0~72hours</time_frame>
    <description>Amlodipine, valsartan, rosuvastatin, free ezetimibe: Cmax,ss</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCτ(N-desmethyl rosuvastatin, total ezetimibe) desmethyl rosuvastatin, total ezetimibe: AUCτ, Cmax,ss</measure>
    <time_frame>0~72hours</time_frame>
    <description>N-desmethyl rosuvastatin, total ezetimibe: AUCτ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss(N-desmethyl rosuvastatin, total ezetimibe) desmethyl rosuvastatin, total ezetimibe: AUCτ, Cmax,ss</measure>
    <time_frame>0~72hours</time_frame>
    <description>N-desmethyl rosuvastatin, total ezetimibe: Cmax,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss(amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe)</measure>
    <time_frame>0~72hours</time_frame>
    <description>amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe: Cmin,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss(amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe)</measure>
    <time_frame>0~72hours</time_frame>
    <description>amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe: Tmax,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2(amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe)</measure>
    <time_frame>0~72hours</time_frame>
    <description>amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe: t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F(amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe)</measure>
    <time_frame>0~72hours</time_frame>
    <description>amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe: CLss/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F(amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe)</measure>
    <time_frame>0~72hours</time_frame>
    <description>amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe: Vd/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTF(amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe)</measure>
    <time_frame>0~72hours</time_frame>
    <description>amlodipine, valsartan, rosuvastatin, N-desmethyl rosuvastatin, free ezetimibe and, total ezetimibe: PTF</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>ID1801</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>qd daily for 6days Intervention: Drug: administration of ID1801 for 6days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID1803</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>qd daily for 10days Intervention: Drug: administration of ID1803 for 10days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID1801 and ID1803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>qd daily for 7days Intervention: Drug: administration of ID1801 and ID1803.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ID1803</intervention_name>
    <description>Amlodipine 10mg/Valsartan 160mg</description>
    <arm_group_label>ID1803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ID1801</intervention_name>
    <description>Ezetimibe 10mg/Rosuvastatin Ca 20.8mg</description>
    <arm_group_label>ID1801</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ID1803+ID1801</intervention_name>
    <description>Amlodipine 10mg/Valsartan 160mg Ezetimibe 10mg/Rosuvastatin Ca 20.8mg</description>
    <arm_group_label>ID1801 and ID1803</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male volunteers aged 19 to 45 years

          -  Subjects who have over 50kg and BMI more than 18.5kg/m2 and less than 29.9kg/m2

          -  Males must be agree to practice a medically acceptable method* of birth control and
             will not donate sperm during the study.

          -  Subjects who provided written informed consent to participate in this study and
             voluntarily taken part in during the entire study period

        Exclusion Criteria:

          -  Subject with serious active cardiovascular, respiratory, hepatologic, renal,
             hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological
             disease or history of such disease

          -  Subject with symptoms of acute disease within 28days prior to study medication dosing

          -  Medical history or evidence that can affect absorption, distribution, metabolism and
             excretion of a given drug

          -  Drugs or other drugs (aspirin, antibiotics, etc.) that contain the following drug
             categories or components of the same strain have an overactive or clinically
             significant history of hypersensitivity:

          -  Subject with a history of drug abuse or urinalysis positive

          -  Subject with clinically significant active chronic disease

          -  Subject with genetic problems such as galactose intolerance, Lapp lactose deficiency
             or glucose-galactose malabsorption.

          -  Genetic myopathic disorder or related family history

          -  Positive test results for HBs Ab, HCV Ab, Anti HIV(AIDS), RPR Ab

          -  Subject with clinically significant allergic disease (except for mild allergic
             rhinitis and mild allergic dermatitis that are not needed to administer drug)

          -  Subject who cannot take standard meal in hospitalization

          -  Present history of hypothyroidism or clinically significant assay

          -  Subjects who donated whole blood or partial blood within 2 or 1 month, respectively,
             prior to the first administration.

          -  Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within
             30days prior to study medication dosing

          -  Smokers whose average daily smoking amount exceeds 10 cigarettes per day within 3
             months before the first dosing day and those who can't quit from 48 hours before
             dosing to the time of the last blood sampling.

          -  Subjects who judged ineligible by the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 22, 2019</last_update_submitted>
  <last_update_submitted_qc>December 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

